Pre-Made Efanesoctocog Alfa Biosimilar, Fusion Protein targeting F8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-809

Pre-Made Efanesoctocog Alfa Biosimilar, Fusion Protein targeting F8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efanesoctocog alfa is an investigational and longer-lasting factor VIII (FVIII) replacement therapy for people with hemophilia A. Efanesoctocog alfa is based on Fc fusion technology, and is made by adding a region of a blood-clotting protein called von Willebrand factor (VWF) and a polypeptide called XTEN to a recombinant, or man-made, FVIII-Fc fusion protein

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-809-1mg 1mg 3090
GMP-Bios-INN-809-10mg 10mg Inquiry
GMP-Bios-INN-809-100mg 100mg Inquiry
GMP-Bios-INN-809-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Efanesoctocog Alfa Biosimilar, Fusion Protein targeting F8 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E
INN Name Efanesoctocog Alfa
TargetF8
FormatFusion Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeFusion - F8 (coagulation factor VIII) with deleted B- domain - VWF (von Willebrand factor) - XTEN - IGHG1 Fc (Fragment constant)
VD LCFusion - F8 (coagulation factor VIII) with deleted B- domain - VWF (von Willebrand factor) - XTEN - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesBiogen, Inc. (Cambridge MA USA) / Amunix (Moutain View CA USA) / Bioverativ, Inc. (Waltham MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0